SAFC expands Pharmorphix UK site
SAFC, a member of the Sigma-Aldrich Group, has completed the initial phase of a two-stage expansion at its SAFC Pharmorphix research facility in Cambridge, UK, for its SAFC Pharma business.
SAFC, a member of the Sigma-Aldrich Group, has completed the initial phase of a two-stage expansion at its SAFC Pharmorphix research facility in Cambridge, UK, for its SAFC Pharma business.
Completion of a 2,500ft2 laboratory extension will be followed by additional investment in spring 2007 as part of a US$600,000 expansion programme.
SAFC Pharmorphix is one of a few organisations specialising in solid form characterisation and research. These services focus on understanding and modifying the physical properties of Active Pharmaceutical Ingredients (APIs) to ensure patient benefit, optimise product development and protect intellectual property. Services include polymorph investigation, salt selection, physiochemical property determinations, pre-formulation profiling, co-crystallisation, classical chiral resolution and crystallisation studies.
The expanded laboratory will support expected growth in addition to developing analytical techniques. In the second quarter of 2007, SAFC Pharmorphix expects to introduce additional X-ray crystallography equipment into the lab.
Last November, SAFC Pharma announced plans to expand Pharmorphix' capabilities into the US with a new laboratory at their flagship high potency APIs facility in Madison, Wisconsin. The new American lab is expected to be operational in spring 2007.